Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases.
Acetylglucosaminidase
/ genetics
Animals
Aortic Diseases
/ diagnostic imaging
Disease Models, Animal
Echocardiography
Fabry Disease
/ complications
Glycogen Storage Disease Type II
/ complications
Lysosomal Storage Diseases
/ complications
Male
Mice
Mice, Knockout
Mucopolysaccharidosis III
/ complications
alpha-Galactosidase
/ genetics
alpha-Glucosidases
/ genetics
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
25
10
2019
accepted:
27
04
2020
entrez:
20
5
2020
pubmed:
20
5
2020
medline:
1
8
2020
Statut:
epublish
Résumé
Lysosomal storage diseases (LSDs) are rare inherited metabolic diseases characterized by an abnormal accumulation of various toxic materials in the cells as a result of enzyme deficiencies leading to tissue and organ damage. Among clinical manifestations, cardiac diseases are particularly important in Pompe glycogen storage diseases (PD), in glycosphingolipidosis Fabry disease (FD), and mucopolysaccharidoses (MPS). Here, we evaluated the occurrence of aortopathy in knock out (KO) mouse models of three different LSDs, including PD, FD, and MPS IIIB. We measured the aortic diameters in 15 KO male mice, 5 for each LSD: 5 GLA-/- mice for FD, 5 NAGLU-/- mice for MPS IIIB, 5 GAA-/- mice for PD, and 15 wild type (WT) mice: 5 for each strain. In order to compare the aortic parameters between KO and WT mice deriving from the same colonies, different diameters were echocardiographically measured: aortic annulus, aortic sinus, sino-tubular junction, ascending aorta, aortic arch and descending aorta. Storage material content and aortic defects of the KO mice were also analyzed by histology, when available. Compared to their correspondent WT mice: GAA-/- mice showed greater diameters of ascending aorta (1.61mm vs. 1.11mm, p-value = 0.01) and descending aorta (1.17mm vs 1.02mm, p-value 0.04); GLA-/- mice showed greater diameters of aortic annulus (1.35mm vs. 1.22mm, p-value = 0.01), sinus of Valsalva (1.6mm vs. 1.38mm, p-value<0.01), ascending aorta (1.57mm vs. 1.34mm, p-value<0.01), aortic arch (1.36mm vs. 1.22mm, p-value = 0.03) and descending aorta (1.29mm vs. 1.11mm, p-value<0.01); NAGLU-/- mice showed greater diameters of sinus of Valsalva (1.46mm vs. 1.31mm, p-value = 0.05), ascending aorta (1.42mm vs. 1.29mm, p-value<0.01), aortic arch (1.34mm vs. 1.28mm, p-value<0.01) and descending aorta (1.18mm vs. 1.1mm, p-value 0.01). We evaluated for the first time the aortic diameters in 3 LSD mouse models and identified different aortopathy patterns, in concordance with recent human findings. Our results are relevant in view of using KO mouse models for efficiently testing the efficacy of new therapies on distinct cardiovascular aspects of LSDs.
Identifiants
pubmed: 32428018
doi: 10.1371/journal.pone.0233050
pii: PONE-D-19-29826
pmc: PMC7236983
doi:
Substances chimiques
alpha-Glucosidases
EC 3.2.1.20
alpha-Galactosidase
EC 3.2.1.22
alpha-N-acetyl-D-glucosaminidase
EC 3.2.1.50
Acetylglucosaminidase
EC 3.2.1.52
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0233050Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Heart Vessels. 2019 Feb;34(2):290-295
pubmed: 30136169
Eur Heart J. 2010 Feb;31(3):347-53
pubmed: 19850557
Neuromuscul Disord. 2012 Jun;22(6):549-57
pubmed: 22397866
Anat Rec (Hoboken). 2011 Mar;294(3):384-90
pubmed: 21308996
Echocardiography. 2017 Feb;34(2):240-249
pubmed: 28070903
Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2540-4
pubmed: 9122231
Neurotherapeutics. 2018 Oct;15(4):928-942
pubmed: 30117059
PLoS One. 2015 Jul 06;10(7):e0131662
pubmed: 26147524
J Inherit Metab Dis. 2019 Mar;42(2):276-285
pubmed: 30671988
Ital J Pediatr. 2018 Nov 16;44(Suppl 2):122
pubmed: 30442163
Cardiovasc Pathol. 2019 Mar - Apr;39:12-24
pubmed: 30594732
J Inherit Metab Dis. 2011 Dec;34(6):1183-97
pubmed: 21744090
Int J Cardiol. 2007 Aug 9;120(1):138-41
pubmed: 17084921
Eur J Cardiothorac Surg. 2013 Jan;43(1):193-5
pubmed: 22945242
J Biol Chem. 1998 Jul 24;273(30):19086-92
pubmed: 9668092
Arch Argent Pediatr. 2019 Aug 1;117(4):271-278
pubmed: 31339275
Biochim Biophys Acta Mol Basis Dis. 2019 Nov 1;1865(11):165539
pubmed: 31465828
Mol Ther. 2015 Jul;23(7):1138-1148
pubmed: 25881001
Handb Clin Neurol. 2015;132:231-48
pubmed: 26564084
Annu Rev Med. 2015;66:471-86
pubmed: 25587658
J Cardiovasc Echogr. 2018 Apr-Jun;28(2):120-123
pubmed: 29911009
Heart. 2016 Aug 15;102(16):1257-62
pubmed: 27102649
Mol Ther Methods Clin Dev. 2018 Jun 18;10:8-16
pubmed: 29942826
Skin Therapy Lett. 2018 Mar;23(2):4-6
pubmed: 29562089
Mol Genet Metab. 2010 Apr;99(4):396-407
pubmed: 20044292
Mol Genet Metab. 2011 Aug;103(4):362-6
pubmed: 21605996
Ann Transl Med. 2019 Jul;7(13):292
pubmed: 31392204
Biochim Biophys Acta Gen Subj. 2020 Jan;1864(1):129437
pubmed: 31526868
Ann Transl Med. 2018 Dec;6(24):476
pubmed: 30740407
Int J Mol Sci. 2016 Nov 29;17(12):
pubmed: 27916847
Mol Genet Metab. 2011 Dec;104(4):608-19
pubmed: 21944884
Mol Genet Metab. 2018 Jun;124(2):131-134
pubmed: 29735373
Genet Med. 2019 Mar;21(3):591-600
pubmed: 29997386
Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14505-10
pubmed: 10588735
Cell Death Dis. 2018 Jan 18;9(2):40
pubmed: 29348482
Cardiovasc Ultrasound. 2011 Dec 08;9:39
pubmed: 22151912
Biochimie. 2014 Oct;105:211-5
pubmed: 24997405
Nat Rev Dis Primers. 2018 Oct 1;4(1):27
pubmed: 30275469
Future Cardiol. 2017 Nov;13(6):521-527
pubmed: 28936893